Since RANKL and IL-6, ccRCC previously published antigens46, were strongly correlated with immunotherapy resistance71–73, we run additional stainings for PD-L1 and PD-L2 in our ccRCC already reported46 heterogeneous cohort by RPPA. The gene discussed is IL6; the disease is nonpapillary renal cell carcinoma.